266 related articles for article (PubMed ID: 29208771)
1. Advanced iron-overload cardiomyopathy in a genetic murine model is rescued by resveratrol therapy.
Das SK; Zhabyeyev P; Basu R; Patel VB; Dyck JRB; Kassiri Z; Oudit GY
Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29208771
[TBL] [Abstract][Full Text] [Related]
2. Females Are Protected From Iron-Overload Cardiomyopathy Independent of Iron Metabolism: Key Role of Oxidative Stress.
Das SK; Patel VB; Basu R; Wang W; DesAulniers J; Kassiri Z; Oudit GY
J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28115312
[TBL] [Abstract][Full Text] [Related]
3. Iron-overload injury and cardiomyopathy in acquired and genetic models is attenuated by resveratrol therapy.
Das SK; Wang W; Zhabyeyev P; Basu R; McLean B; Fan D; Parajuli N; DesAulniers J; Patel VB; Hajjar RJ; Dyck JR; Kassiri Z; Oudit GY
Sci Rep; 2015 Dec; 5():18132. PubMed ID: 26638758
[TBL] [Abstract][Full Text] [Related]
4. Restoring the impaired cardiac calcium homeostasis and cardiac function in iron overload rats by the combined deferiprone and N-acetyl cysteine.
Wongjaikam S; Kumfu S; Khamseekaew J; Chattipakorn SC; Chattipakorn N
Sci Rep; 2017 Mar; 7():44460. PubMed ID: 28287621
[TBL] [Abstract][Full Text] [Related]
5. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy.
Oudit GY; Sun H; Trivieri MG; Koch SE; Dawood F; Ackerley C; Yazdanpanah M; Wilson GJ; Schwartz A; Liu PP; Backx PH
Nat Med; 2003 Sep; 9(9):1187-94. PubMed ID: 12937413
[TBL] [Abstract][Full Text] [Related]
6. Resveratrol mediates therapeutic hepatic effects in acquired and genetic murine models of iron-overload.
Das SK; DesAulniers J; Dyck JR; Kassiri Z; Oudit GY
Liver Int; 2016 Feb; 36(2):246-57. PubMed ID: 26077449
[TBL] [Abstract][Full Text] [Related]
7. TIMP3 deficiency exacerbates iron overload-mediated cardiomyopathy and liver disease.
Zhabyeyev P; Das SK; Basu R; Shen M; Patel VB; Kassiri Z; Oudit GY
Am J Physiol Heart Circ Physiol; 2018 May; 314(5):H978-H990. PubMed ID: 29373036
[TBL] [Abstract][Full Text] [Related]
8. Amlodipine rescues advanced iron overload cardiomyopathy in hemojuvelin knockout murine model: Clinical implications.
Zhabyeyev P; Sadasivan C; Shah S; Wang F; Oudit GY
Front Cardiovasc Med; 2023; 10():1129349. PubMed ID: 37153462
[TBL] [Abstract][Full Text] [Related]
9. Effect of L-type calcium channel blocker (amlodipine) on myocardial iron deposition in patients with thalassaemia with moderate-to-severe myocardial iron deposition: protocol for a randomised, controlled trial.
Shakoor A; Zahoor M; Sadaf A; Alvi N; Fadoo Z; Rizvi A; Quadri F; Tipoo FA; Khurshid M; Sajjad Z; Colan S; Hasan BS
BMJ Open; 2014 Dec; 4(12):e005360. PubMed ID: 25492271
[TBL] [Abstract][Full Text] [Related]
10. Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy.
Sulaiman M; Matta MJ; Sunderesan NR; Gupta MP; Periasamy M; Gupta M
Am J Physiol Heart Circ Physiol; 2010 Mar; 298(3):H833-43. PubMed ID: 20008278
[TBL] [Abstract][Full Text] [Related]
11. Hfe and Hjv exhibit overlapping functions for iron signaling to hepcidin.
Kent P; Wilkinson N; Constante M; Fillebeen C; Gkouvatsos K; Wagner J; Buffler M; Becker C; Schümann K; Santos MM; Pantopoulos K
J Mol Med (Berl); 2015 May; 93(5):489-98. PubMed ID: 25609138
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and treatment of cardiac iron overload in transfusion-dependent thalassemia patients.
Siri-Angkul N; Chattipakorn SC; Chattipakorn N
Expert Rev Hematol; 2018 Jun; 11(6):471-479. PubMed ID: 29754517
[TBL] [Abstract][Full Text] [Related]
13. Hepatocyte neogenin is required for hemojuvelin-mediated hepcidin expression and iron homeostasis in mice.
Enns CA; Jue S; Zhang AS
Blood; 2021 Aug; 138(6):486-499. PubMed ID: 33824974
[TBL] [Abstract][Full Text] [Related]
14. mRNA regulation of cardiac iron transporters and ferritin subunits in a mouse model of iron overload.
Brewer CJ; Wood RI; Wood JC
Exp Hematol; 2014 Dec; 42(12):1059-67. PubMed ID: 25220979
[TBL] [Abstract][Full Text] [Related]
15. The C57BL/6 genetic background confers cardioprotection in iron-overloaded mice.
Musumeci M; Maccari S; Sestili P; Massimi A; Corritore E; Marano G; Catalano L
Blood Transfus; 2013 Jan; 11(1):88-93. PubMed ID: 22790263
[TBL] [Abstract][Full Text] [Related]
16. Loss of NOX2 (gp91phox) prevents oxidative stress and progression to advanced heart failure.
Parajuli N; Patel VB; Wang W; Basu R; Oudit GY
Clin Sci (Lond); 2014 Sep; 127(5):331-40. PubMed ID: 24624929
[TBL] [Abstract][Full Text] [Related]
17. Iron overload exacerbates age-associated cardiac hypertrophy in a mouse model of hemochromatosis.
Sukumaran A; Chang J; Han M; Mintri S; Khaw BA; Kim J
Sci Rep; 2017 Jul; 7(1):5756. PubMed ID: 28720890
[TBL] [Abstract][Full Text] [Related]
18. Adiponectin ameliorates iron-overload cardiomyopathy through the PPARα-PGC-1-dependent signaling pathway.
Lin H; Lian WS; Chen HH; Lai PF; Cheng CF
Mol Pharmacol; 2013 Aug; 84(2):275-85. PubMed ID: 23723143
[TBL] [Abstract][Full Text] [Related]
19. Establishment of secondary iron overloaded mouse model: evaluation of cardiac function and analysis according to iron concentration.
Moon SN; Han JW; Hwang HS; Kim MJ; Lee SJ; Lee JY; Oh CK; Jeong DC
Pediatr Cardiol; 2011 Oct; 32(7):947-52. PubMed ID: 21656238
[TBL] [Abstract][Full Text] [Related]
20. Duality of Nrf2 in iron-overload cardiomyopathy.
Federti E; Vinchi F; Iatcenko I; Ghigo A; Matte A; Toya SCM; Siciliano A; Chiabrando D; Tolosano E; Vance SZ; Riccardi V; Andolfo I; Iezzi M; Lamolinara A; Iolascon A; De Franceschi L
Haematologica; 2023 May; 108(5):1335-1348. PubMed ID: 36700398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
